Quick Answer
GYRE THERAPEUTICS, INC. reported R&D Expense of $13.70 million for fiscal year 2025.
GYRE THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $13.70M | +13.9% |
| 2024 | $12.02M | -12.7% |
| 2023 | $13.78M | -80.0% |
| 2021 | $68.89M | +30.0% |
| 2020 | $52.98M | +20.8% |
| 2019 | $43.86M | +104.2% |
| 2018 | $21.47M | +67.2% |
| 2017 | $12.85M | +11.2% |
| 2016 | $11.55M | +93.9% |
| 2015 | $5.96M | +13.1% |
| 2014 | $5.27M | -19.7% |
| 2013 | $6.56M | -86.6% |
| 2012 | $49.09M | -48.4% |
| 2011 | $95.22M | +47.5% |
| 2010 | $64.55M | +60.6% |
| 2009 | $40.18M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.36M | -14.8% | -31.0% |
| June 30, 2025 | $3.42M | +2.1% | +10.7% |
| March 31, 2025 | $3.10M | +41.8% | +11.5% |
| September 30, 2024 | $2.77M | -7.8% | -17.3% |
| June 30, 2024 | $3.35M | -6.0% | +53.8% |
| March 31, 2024 | $2.18M | -17.2% | -27.5% |
| September 30, 2023 | $3.01M | +274.7% | -15.7% |
| June 30, 2023 | $3.57M | +90.7% | +35.4% |
- GYRE THERAPEUTICS, INC. showed an increase of +13.9% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, GYRE THERAPEUTICS, INC.’s r&d expense has declined by 65.9% (from $40.18 million to $13.70 million).
- The most recent figure is from GYRE THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: